|
T5036 |
Cangrelor tetrasodium
|
|
GPR
,
P2Y Receptor
|
|
Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects. |
|
T9592 |
OATD-01
|
|
Others
|
|
OATD-01 is a highly active inhibitor of both Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase). |
|
T9688 |
CC-90001
|
|
JNK
|
|
CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2. |
|
T9699 |
TAK-615
|
|
LPA Receptor
|
|
TAK-615 is commonly used to study pulmonary fibrosis and is a negative allosteric modulator of LPA1 receptors. |
|
T1841 |
UNC0379
|
|
Histone Methyltransferase
|
|
UNC0379 is a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. |
|
T0239 |
Lonidamine
|
AF1890,DICA,Diclondazolic Acid |
Apoptosis
,
Hexokinase
,
Mitochondrial Metabolism
|
|
Lonidamine (Diclondazolic Acid) is an indazole carboxylic acid derivative, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). |
|
T23322 |
SB 452533
|
|
TRP/TRPV Channel
|
|
SB 452533 is an antagonist of the vanilloid receptor 1(pKb: 7.8). |
|
T4503 |
Talniflumate
|
Somalgen |
Chloride channel
,
COX
,
N-Acetylglucosaminyltransferase
,
Anion Exchanger
|
|
Talniflumate (Somalgen) is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture. It possesses anti-inflammatory actions via inhibition o... |
|
T2561 |
Macitentan
|
ACT-064992 |
Apoptosis
,
Endothelin Receptor
|
|
Macitentan (ACT-064992) is an endothelin receptor antagonist that is used in the therapy of pulmonary arterial hypertension (PAH). |
|
T4016 |
BMS-986020
|
AM152,BMS986020 |
LPA Receptor
,
LPL Receptor
|
|
BMS-986020 (AM152) is a selective antagonist of LPA1. |
|
T2663 |
GTS-21 dihydrochloride
|
GTS 21 dihydrochloride,DMXB-A,DMBX-anabaseine |
5-HT Receptor
,
AChR
|
|
GTS-21 dihydrochloride (DMBX-anabaseine) is a nAChRs agonist. nAChRs are neuron receptor proteins that activated by the binding of the neurotransmitter ACh. |
|
TP1016L |
Aviptadil Acetate
|
Vasoactive Intestinal Peptide acetate salt |
RAAS
,
SARS-CoV
|
|
Aviptadil Acetate (Vasoactive Intestinal Peptide acetate salt) induces pulmonary vasodilation and inhibits the proliferation of vascular SMCs and platelet aggregation. Avitadil acetate can be used for research on pulmona... |
|
T9199 |
GLPG2938
|
1-(2-Ethoxy-6-(trifluoromethyl)pyridin-4-yl)-3-((5-methyl-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl)urea |
S1P Receptor
,
LPL Receptor
|
|
GLPG2938 (1-(2-Ethoxy-6-(trifluoromethyl)pyridin-4-yl)-3-((5-methyl-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl)urea) is a potent and selective antagonist of S1P2. |
|
T4041 |
Ziritaxestat
|
GLPG1690 |
PDE
|
|
Ziritaxestat (GLPG1690), an autotaxin inhibitor, currently being evaluated in an exploratory phase 2 study in idiopathic pulmonary fibrosis patients. |
|
T69665 |
Zelasudil
|
RXC007 |
ROCK
|
|
Zelasudil (RXC007) is a Rho-related (ROCK) kinase inhibitor for the study of idiopathic pulmonary fibrosis and inflammation. |
|
T60226 |
CT52923
|
|
PDGFR
|
|
CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological dis... |
|
T76856 |
Andecaliximab
|
GS-5745 |
MMP
,
Virus Protease
|
|
Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used ... |
|
T75004 |
TGFβ1-IN-2
|
|
Others
|
|
TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research [1]. |
|
T83168 |
Aderamastat
|
FP-003,FP-025 |
MMP
|
|
Aderamastat (FP-025) is an orally active matrix metalloproteinase 12 (MMP-12) inhibitor indicated for the study of allergic asthma, COPD and pulmonary fibrosis. |
|
T72031 |
BI 1015550
|
|
PDE
|
|
BI 1015550 is an orally active inhibitor of PDE4B with an IC 50 value of 7.2 nM. BI 1015550 has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmo... |
|
T15785 |
LPA1 receptor antagonist 1
|
LPA1 R antagonist 1 |
LPA Receptor
|
|
LPA1 receptor antagonist 1(LPA1 R antagonist 1) is a selective and potent lysophosphatidic acid (LPA1) receptor antagonist (IC50 : 25 nM) for the study of idiopathic pulmonary fibrosis. |
|
T72918 |
JNJ-49095397
|
RV568 |
Antiviral
,
p38 MAPK
|
|
JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and resp... |
|
T75005 |
TGFβ1-IN-3
|
|
Others
|
|
TGFβ1-IN-3 is a diarylhydrazone derivative with inhibitory effects on fibroblast activation and proliferation.TGFβ1-IN-3 is a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF). |
|
T11411 |
GLPG1205
|
|
GPR
,
Others
|
|
GLPG1205 is a potent, orally active GPR84 (G protein-coupled receptor) antagonist with anti-inflammatory activity. GLPG1205 shows good PK/PD characteristics and can be used to study pulmonary fibrosis. |
|
T39647 |
BMS-986278
|
|
LPA Receptor
|
|
BMS-986278 is an orally active and potent hemophosphatidic acid receptor 1 (LPA1) antagonist with Kb values of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively.BMS-986278 may be investigated for use in idiopathic... |
|
T39719 |
Nrf2 activator-1
|
Nrf2 activator-1 |
Nrf2
|
|
Nrf2 activator-1 is a potent activator of NF-E2-related factor 2 (Nrf2).Nrf2 activator-1 can be used to study COPD and other respiratory diseases including asthma, acute lung injury (ALI), acute respiratory distress synd... |
|
T76956 |
Vixarelimab
|
RG-6536,RO-7622888,KPL-716 |
Interleukin
|
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor and inhibition of IL-31 and OSM signaling.Vixarelimab can be used to study severe nodular ... |
|
T39933 |
Bexotegrast
|
PLN-74809 |
Integrin
|
|
Bexotegrast (PLN-74809) is an orally active and potent inhibitor of αvβ6 and αvβ1 integrins with antifibrotic effects, inhibits αvβ6 and αvβ1-induced activation of TGF-β, and can be used for the study of idiopathic pulmo... |
|
T10417 |
Autotaxin-IN-5
|
|
PDE
|
|
Autotaxin-IN-5 is an Autotaxin inhibitor. It has the potential to treat idiopathic pulmonary fibrosis. |
|
T25136 |
Aztreonam lysine
|
Corus 1020,Corus1020,Corus-1020,Aztreonam lysinate |
|
|
Aztreonam lysine is an inhaled anti-pseudomonal treatment for people who have pulmonary Pseudomonas aeruginosa infection with cystic fibrosis (CF). |
|
T28177 |
NK3201
|
NK-3201,NK 3201 |
|
|
NK3201, a specific chymase inhibitor, suppresses bleomycin-induced pulmonary fibrosis in hamsters. |
|
T10416 |
Autotaxin-IN-4
|
|
PDE
|
|
Autotaxin-IN-4 is an Autotaxin inhibitor. It has the potential to treat idiopathic pulmonary fibrosis. |
|
T16434 |
PAT-048
|
|
PDE
|
|
PAT-048 is an effective and selective autotaxin inhibitor. PAT-048 reduces dermal fibrosis in vivo. PAT-048 also inhibits IL-6 mRNA expression but displays no effect on autotaxin protein and pulmonary lysophosphatidic ac... |
|
T79543 |
J27644
|
|
HDAC
|
|
J27644 is a potent HDAC (histone deacetylase) inhibitor that mitigates TGF-β (transforming growth factor beta)-induced pulmonary fibrosis [1]. |
|
T11935 |
Macitentan (n-butyl analogue)
|
|
Others
|
|
Macitentan n-butyl analogue, a derivative of Macitentan, functions as an orally active dual antagonist targeting both endothelin ETA and ETB receptors. This compound shows promise for treating idiopathic pulmonary fibros... |
|
T73662 |
Peplomycin
|
|
|
|
Peplomycin (Bleomycin PEP; Pepleomycin), an analogue of Bleomycin, exhibits significant antitumor activity with reduced pulmonary toxicity. It induces apoptosis in the oral squamous carcinoma cell line SSCKN and causes p... |
|
T74632 |
TP0556351
|
|
MMP
|
|
TP0556351, a potent and selective inhibitor of matrix metalloproteinase-2 (MMP2), exhibits significant efficacy with an IC50 of 0.2 nM and demonstrates the capability to decrease collagen accumulation in a Bleomycin-indu... |
|
T77031 |
Ifabotuzumab
|
|
|
|
Ifabotuzumab (KB004), an IgG1κ antibody, specifically binds to EphA3 (K D =610 pM), inducing tumor cell apoptosis, activating antibody-dependent cell-mediated cytotoxicity (ADCC), and damaging tumor vasculature. Addition... |
|
T69517 |
Bexotegrast HCl
|
|
|
|
Bexotegrast, also known as PLN-74809, is a small-molecule, dual selective inhibitor of αVβ1 / αVβ6 for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). These integrins cause upstream activati... |
|
T76804 |
FG-3019
|
|
|
|
Pamrevlumab (FG-3019) is a recombinant human antibody targeting connective tissue growth factor (CTGF), with potential applications in idiopathic pulmonary fibrosis (IPF) research [1] [2]. |
|
T72380 |
PI3K/mTOR Inhibitor-13
|
|
|
|
PI3K/mTOR Inhibitor-13, an orally active dual inhibitor targeting phosphoinositol 3-kinase (PI3K) and mTOR kinase, holds potential for treating sexual diseases, solid tumors, and idiopathic pulmonary fibrosis (IPF). |
|
T63486 |
DPPY
|
|
|
|
DPPY is a potent inhibitor of PTK that acts on EGFR (IC50<10 nM), BTK (IC50<10 nM), and JAK3 (IC50<10 nM). DPPY inhibits the proliferation of B-cell lymphoma cells and has potential for investigation in idiopathic pulmon... |
|
T28788 |
SK-216
|
SK216.Plasminogen activator inhibitor-1 (PAI-1) inhibitor |
|
|
SK-216 is a specific PAI-1 inhibitor. SK-216 reduced the extent of angiogenesis in the tumors and inhibited VEGF-induced migration and tube formation by human umbilical vein endothelial cells in vitro. SK-216 reduced the... |
|
T82313 |
GK718
|
|
HDAC
|
|
GK718, a selective HDAC1/3 inhibitor with IC50 values of 259 nM and 139 nM, respectively, elevates acetylated histone H3 levels in cells and mitigates Bleomycin-induced pulmonary fibrosis in mice [1]. |
|
T74402 |
FAP-PI3KI1
|
|
|
|
FAP-PI3KI1, a fibroblast-activated protein (FAP)-targeted PI3K inhibitor, selectively targets FAP-expressing human idiopathic pulmonary fibrosis (IPF) cells. It effectively inhibits collagen synthesis and reduces collage... |
|
T73035 |
STAT3-IN-15
|
|
|
|
STAT3-IN-15, a potent and orally active inhibitor targeting STAT3, effectively combats idiopathic pulmonary fibrosis (IPF) by hindering STAT3 phosphorylation. Additionally, it impedes TGF-β1-induced migration and deforma... |
|
T63439 |
BMS-986020 sodium
|
|
|
|
BMS-986020 sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist that inhibits bile acids and phospholipid transport proteins, and inhibits BSEP (IC50: 4.8 μM), MRP4 (IC50: 6.2 μM) and MDR3 (IC50: ... |
|
T62909 |
SGC agonist 2
|
|
|
|
SGC agonist 2 is a potent soluble guanylate cyclase (SGC) agonist. SGC agonist 2 has potential for cardiovascular disease (heart failure, angina, pulmonary hypertension, myocardial infarction) and fibrotic disease (renal... |
|
T80697 |
β5i-IN-1
|
|
Proteasome
|
|
β5i-IN-1 is a selective inhibitor of β5i, exhibiting potent activity with an IC50 of 8.463 nM. It modulates immune responses by promoting the release of TNF-α and IL-6 and affecting NF-κB transcriptional activity. This c... |
|
T64008 |
Thi-DPPY
|
|
|
|
Thi-DPPY is a potent, orally active JAK3 inhibitor that acts on BTK (IC50: 62.4 nM), JAK (IC50: 1.38 nM). Thi-DPPY is anti-proliferative against HBE cells. Thi-DPPY has anti-inflammatory effects in vivo. Thi-DPPY has sho... |
